IRIS
PIVONELLO, ROSARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.123
EU - Europa 2.858
AS - Asia 899
AF - Africa 98
SA - Sud America 11
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
Totale 8.997
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.976
IT - Italia 833
CN - Cina 733
NL - Olanda 417
SE - Svezia 340
IE - Irlanda 310
FI - Finlandia 292
DE - Germania 266
UA - Ucraina 189
CA - Canada 139
CI - Costa d'Avorio 96
FR - Francia 79
GB - Regno Unito 73
IN - India 42
TR - Turchia 40
IR - Iran 22
ES - Italia 15
SG - Singapore 15
VN - Vietnam 15
RU - Federazione Russa 12
BE - Belgio 8
IQ - Iraq 8
JO - Giordania 7
RO - Romania 7
MX - Messico 6
AU - Australia 4
EU - Europa 4
ID - Indonesia 4
PH - Filippine 4
AT - Austria 3
CZ - Repubblica Ceca 3
HK - Hong Kong 3
AR - Argentina 2
CL - Cile 2
EC - Ecuador 2
GR - Grecia 2
LK - Sri Lanka 2
PE - Perù 2
SI - Slovenia 2
AM - Armenia 1
BG - Bulgaria 1
BO - Bolivia 1
BR - Brasile 1
CH - Svizzera 1
CO - Colombia 1
CR - Costa Rica 1
DK - Danimarca 1
EG - Egitto 1
HR - Croazia 1
KR - Corea 1
LB - Libano 1
LU - Lussemburgo 1
NG - Nigeria 1
NO - Norvegia 1
PA - Panama 1
PL - Polonia 1
TH - Thailandia 1
Totale 8.997
Salva come PNG Salva come JPEG
Città #
Chandler 1.123
Millbury 473
Amsterdam 400
Princeton 302
Jacksonville 271
Nanjing 258
Naples 202
Wilmington 197
Ashburn 195
Napoli 138
Boston 134
Beijing 122
Des Moines 121
Ottawa 111
Woodbridge 84
Lawrence 78
Nanchang 76
Hebei 58
Houston 48
Shenyang 42
Ann Arbor 37
Norwalk 34
Jiaxing 31
Kronberg 31
Tianjin 31
Falls Church 28
Seattle 28
Changsha 26
San Mateo 26
Boardman 24
Rome 22
Pune 18
Redwood City 18
Ardabil 17
Dublin 17
Indiana 17
Kunming 16
Dong Ket 15
New York 14
Cagliari 13
Redmond 13
Fairfield 12
Lappeenranta 12
Casoria 11
Los Angeles 11
Augusta 10
Montreal 10
Dearborn 9
Jinan 9
Marigliano 9
Portici 9
Shanghai 9
Singapore 9
Bari 8
Hangzhou 8
Lanzhou 8
Washington 8
Frankfurt am Main 7
Molina de Segura 7
San Francisco 7
Toronto 7
Catania 6
Leawood 6
London 6
Milan 6
Paris 6
Villa Literno 6
Buffalo 5
Caserta 5
Changchun 5
Livorno 5
Menlo Park 5
Padova 5
Tappahannock 5
Turin 5
Afragola 4
Bologna 4
Mexico 4
Modena 4
Mountain View 4
Mugnano Di Napoli 4
Sainte-Marthe-sur-le-Lac 4
Stockholm 4
Torino 4
Zhengzhou 4
Altamura 3
Campobasso 3
Carbonara di Nola 3
Castellammare Di Stabia 3
Castellammare di Stabia 3
Chicago 3
Courcelles 3
Danvers 3
Dogliani 3
Edinburgh 3
Falkenstein 3
Florence 3
Fuzhou 3
Istanbul 3
Konya 3
Totale 5.250
Salva come PNG Salva come JPEG
Nome #
Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age 78
Flavor perception test: evaluation in patients with Kallmann syndrome 74
Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency 69
Spot-light on microbiota in obesity and cancer 68
Antipituitary antibodies in idiopathic hyperprolactinemic patients 63
Cabergoline plus lanreotide for ectopic Cushing's syndrome. 62
"Realizzazione, sperimentazione, messa a punto, sviluppo e reindustrializzazione di un metodo biomolecolare integrato (“hepatochip”) per la caratterizzazione diagnostica e prognostica di lesioni epatiche correlate o meno ad infezioni virali" 59
Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly 58
Adverse events associated with somatostatin analogs in acromegaly. 57
Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism 57
Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients 56
Weekly clodronate treatment prevents bone loss and vertebral fractures in womenwith subclinical Cushing's syndrome. 56
Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours 54
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance 54
The 17β-hydroxysteroid dehydrogenase type 3 deficiency: a case report of an 18-year patient and review of the literature. 54
Neuropsychiatric disorders in Cushing's syndrome. 53
Sulfur amino acids in Cushing's disease: insight in homocysteine and taurine levels in patients with active and cured disease 53
The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. 51
Reduced bone mineral density in glycogen storage disease type III: Evidence for a possible connection between metabolic imbalance and bone homeostasis 51
A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients 50
Accordi di programma "Piattaforme tecnologiche avanzate per la definizione di nuovi biomarkers e bersagli molecolari in vettori nanotecnologici per la diagnosi e la terapia di neoplasie umane" 50
Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy. 49
Recombinant thyrotropin-induced orbital uptake of [111In-diethylenetriamine-pentacetic acid-D-Phe1]octreotide in a patient with inactive Graves' ophthalmopathy. 49
Selenium supplementation modulates apoptotic processes in thyroid follicular cells 49
The Treatment of Cushing's Disease. 48
Increased prevalence of thyroid autoimmunity and hypothyroidism in patients with glycogen storage disease type I 48
The GH-IGF system in amyotrophic lateral sclerosis: correlations between pituitary GH secretion capacity, insulin-like growth factors and clinical features. 48
Air pollution and female fertility: A systematic review of literature 48
Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. 47
The environment and male reproduction: The effect of cadmium exposure on reproductive functions and its implication in fertility 47
Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly 47
Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation. 46
Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status 46
The natural history of partial growth hormone deficiency in adults: a prospective study on the cardiovascular risk and atherosclerosis. 45
The role of vitamin D in male fertility: A focus on the testis 45
CONVENTIONAL AND NUCLEAR MEDICINE IMAGING IN ECTOPIC CUSHING'S SYNDROME: A SYSTEMATIC REVIEW. 44
The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients 44
First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. 44
Adrenal Mass: Insight Into Pathogenesis and a Common Link With Insulin Resistance 44
Hypertension in acromegaly and in the normal population: prevalence and determinants 43
Comment on Azmahani et al. "Steroidogenic enzymes, their related transcription factors and nuclear receptors in human sebaceous glands under normal and pathological conditions" 43
The effect of FT500 Plus® on ovarian stimulation in PCOS women 43
Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly 42
The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center. 42
Erratum to: The treatment with pasireotide in Cushing’s disease: effects of long–term treatment on tumor mass in the experience of a single center (Endocrine, (2015), 50, (725-740) DOI 10.1007/s12020-015-0557-2) 42
Multiple system atrophy is associated with changes in peripheral insulin-like growth factor system. 41
"Dopamine receptor expression and role of dopamine D2 receptor activation in pituitary and adrenaltumors”. 41
Cabergoline use for pituitary tumors and valvular disorders. 41
Metabolic alterations and cardiovascular outcomes of cortisol excess 41
The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma 41
Complications of Cushing's syndrome: State of the art 41
Germline polymorphisms of the VEGF-pathway predict recurrence in non-advanced differentiated thyroid cancer 41
Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males 40
Pause: Premature ejaculation actual use sefety and effectiveness study. Studio prospettico osservazionale su pazienti con eiaculazione precoce trattati con Priligy o terapie alternative. 40
Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit 40
Circadian rhythm of glucocorticoid administration entrains clock genes in immune cells: a DREAM trial ancillary study 40
A New Clinical Model to Estimate the Pre-Test Probability of Cushing’s Syndrome: The Cushing Score 40
Acromegalic axial arthropathy: a clinical case-control study 39
Cushing's syndrome: aftermath of the cure. 39
The Glucocorticoid Analog Dexamethasone Alters the Expression and the Distribution of Dopamine Receptors and Enkephalin within Cortico-subcortical Regions. 39
Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome 38
Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission 38
Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. 38
Bisphenol A: An emerging threat to female fertility 38
Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE). 38
Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease. 38
Cushing's syndrome 37
Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: A retrospective, comparative, head-to-head study 37
Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study. 37
Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. 37
Pegvisomant in acromegaly: why, when, how 36
Short-term suppression of GH and IGF-I levels improves gonadal function and sperm parameters in men with acromegaly 36
Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency. 36
Growth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects. 36
Evaluation of the retinal nerve fibre layer and ganglion cell complex thickness in pituitary macroadenomas without chiasmal compression. 36
Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities 36
Correlation between Morphometric parameters and chromatin fragmentation in spermatozoa of Canis familiaris. 36
Increased IGF-I : IGFBP-3 ratio in patients with hepatocellular carcinoma 35
Cardiovascular disease in Cushing's syndrome: heart versus vasculature. 35
Effects of initial therapy for five years with somatostatin analogs foracromegaly on growth hormone and insulin-like growth factor-I levels, tumorshrinkage, and cardiovascular disease: a prospective study. 35
The role of inferior petrosal sinus sampling in ACTH-dependent Cushing's syndrome:review and joint opinion statement by members of the Italian Society for Endocrinology, Italian Society for Neurosurgery, and Italian Society for Neuroradiology 35
Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study 35
Cushing’s disease: the burden of illness 35
Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting 35
CORTISOL CIRCADIAN RHYTHM AND INSULIN RESISTANCE IN MUSCLE: EFFECT OF DOSING AND TIMING OF HYDROCORTISONE EXPOSURE ON INSULIN SENSITIVITY IN SYNCHRONIZED MUSCLE CELLS 35
Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas 34
Quality of Life in Patients with Cushing's Disease: A Modern Approach 34
The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. 34
[Chronic kidney disease: fertility and sexuality] 34
Dual targeting of PIK3/AKT/mTOR and IGF1/KRAS/BRAF pathways in an in vitro model of ovarian cancer: strategies for cell proliferation control 34
Cardiovascular alterations in adult GH deficiency 34
Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients 33
A longitudinal study of vasopressin cell antibodies, posterior pituitary function, and magnetic resonance imaging evaluations in subclinical autoimmune central diabetes insipidus 33
Pasireotide treatment reduces cardiometabolic risk in Cushingâ s disease patients: an Italian, multicenter study 33
Acromegaly and the cardiovascular system 32
Early vascular alterations in acromegaly 32
Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-monthstudy. 32
17 beta hyrossisteroid dehydrogenase type 3 deficiency : a new case of a rare disease with uncommon gene mutation 32
The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications 32
Reevaluation of growth hormone (GH) secretion in 69 adults diagnosed as GH-deficient patients during childhood 31
Totale 4.326
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.430
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.430
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201947 0 0 0 0 0 0 0 0 0 0 13 34
2019/20201.025 441 11 36 24 65 29 7 13 20 48 139 192
2020/2021768 19 36 94 50 77 156 46 8 83 32 134 33
2021/20222.214 37 7 10 25 54 215 29 61 372 120 376 908
2022/20232.709 409 227 75 213 329 262 27 230 374 414 112 37
2023/20241.244 86 271 239 142 80 115 49 190 27 40 5 0
Totale 9.540